Improved method of plasma 8-Isoprostane measurement and association analyses with habitual drinking and smoking
We have developed a simple and accurate method for quantifying plasma 8-isoprostane by employing a combination of two-step solid-phase extraction of samples and a commercially available ELISA kit.
When the plasma 8-isoprostane level was measured by using our method, the mean value of 157 healthy volunteers was 20.9 ± 9.3 ng/L, which is almost equal to the reported values using GC/MS or LC/MS[5,24,25]. The level of plasma 8-isoprostane in 4 healthy subjects among these samples measured directly by ELISA without extraction was more than 20-fold higher than those obtained by the combination of the two-step extraction and ELISA (651.5 ± 149.2 vs 24.4 ± 4.1 ng/L). According to 8-Isoprostane EIA kit booklet, although the cross-reactivity of the anti 8-isoprostane antibody employed in the ELISA kit is reported to be low, the extraction of plasma 8-isoprostane from plasma prior to the assay is indispensable. In fact, it has been reported that various 8-isoprostane analogues and related compounds are present at dozens to hundreds of times than the concentration of 8-isoprostane in biological fluids.
In an association study of plasma 8-isoprostane with drinking habits, heavy drinkers were higher than non-habitual drinkers and moderate drinkers. However, the plasma 8-isoprostane level was not significantly different when compared among the 3 male groups. Also, the plasma 8-isoprostane levels were significantly higher in heavy drinkers than in non-habitual and moderate drinkers. This tendency was more prominent in females, and with the ALDH2*21/1 genotype. In other words, the 8-isoprostane level was significantly higher in female habitual drinkers with the ALDH2*2/1 than with the ALDH2*1/1 genotype. These results suggest that excessive drinking may increase oxidative stress, especially in females with the ALDH2*2/1 genotype. When the same amount of alcohol is ingested, females tend to show a higher concentration of blood alcohol than males due to their lower body weight and higher ratio of adipose tissue into which alcohol shows poor penetration. In addition, female hormones, such as estradiol, inhibit the activity of ADH, contributing to the increased concentration of blood alcohol.
Changes in plasma 8-isoprostane levels after alcohol (0.5-1.3 g/kg) intake for 3 d, showed 8-isoprostane significantly increased on d 1, and returned to its original level on d 2. It was previously reported that alcohol consumption induced lipid peroxidation in healthy volunteers, and urinary 8-isoprostane increased in a dose- and time-dependent manner reaching its peak at 0-6 h after ingestion, and through induction of the CYP450 2E1 isozyme, alcohol intake may increase the generation of reactive oxygen intermediates that have the potential to peroxidize lipids[28,29].Similarly, our results may suggest that alcohol ingestion induced oxidative stress in a relatively short time after drinking.
It has been reported that smoking induces oxidative stress and increases urinary 8-isoprostane. Therefore, we compared plasma 8-isoprostane levels in non-smokers and smokers. In contrast to urinary 8-isoprostane, no difference in plasma 8-isoprostane was observed between these 2 groups This is consistent with a previous report measured by LC/MS. The plasma 8-isoprostane may be rapidly metabolized since 75% of plasma 8-isoprostane is excreted in the urine within 4.5 h.
In conclusion, we have developed a simple and accurate method for quantifying plasma 8-isoprostane by employing a combination of two-step solid-phase extraction of samples and a commercially available ELISA kit. Our method fulfilled all the requirements for use in routine clinical assays with respect to sensitivity, intra- and inter-assay reproducibility, accuracy and dynamic assay range. However, the clinical utility of plasma 8-isoprostane for drinking and smoking habits was limited. Further studies using a large population is required for a final conclusion for an association of plasma 8-isoprostane with drinking and smoking habits.
1 Belli R, Amerio P, Brunetti L, Orlando G, Toto P, Proietto G, Vacca M, Tulli A. Elevated 8-isoprostane levels in basal cell carcinoma and in UVA irradiated skin. Int J Immunopathol Pharmacol 2005; 18: 497-502
2 Schwedhelm E, Boger RH. Application of gas chromato-graphy-mass spectrometry for analysis of isoprostanes: their role in cardiovascular disease. Clin Chem Lab Med 2003; 41: 1552-1561
3 Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts LJ 2nd. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87: 9383-9387
4 Chehne F, Oguogho A, Lupattelli G, Budinsky AC, Palumbo B, Sinzinger H. Increase of isoprostane 8-epi-PGF(2alpha)after restarting smoking. Prostaglandins Leukot Essent Fatty Acids 2001; 64: 307-310
5 Ohashi N, Yoshikawa M. Rapid and sensitive quantification of 8-isoprostaglandin F2alpha in human plasma and urine by liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Biomed Sci Appl 2000; 746: 17-24
6 Morita H, Ikeda H, Haramaki N, Eguchi H, Imaizumi T. Only two-week smoking cessation improves platelet aggregability and intraplatelet redox imbalance of long-term smokers. J Am Coll Cardiol 2005; 45: 589-594
7 Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F(2alpha), interleukin-6 and F2-isoprostane formation in elderly men. Atherosclerosis 2005; 181: 201-207
8 Harman SM, Liang L, Tsitouras PD, Gucciardo F, Heward CB, Reaven PD, Ping W, Ahmed A, Cutler RG. Urinary excretion of three nucleic acid oxidation adducts and isoprostane F(2)alpha measured by liquid chromatography-mass spectrometry in smokers, ex-smokers, and nonsmokers. Free Radic Biol Med 2003; 35: 1301-1309
9 Pemberton PW, Smith A, Warnes TW. Non-invasive monitoring of oxidant stress in alcoholic liver disease. Scand J Gastroenterol 2005; 40: 1102-1108
10 Kopczynska E, Lampka M, Torlinski L, Ziolkowski M. The level of 8-iso-prostaglandin F2 alpha, 4-hydroxynonenal and malondialdehyde in alcohol dependent men during combined therapy. Psychiatr Pol 2002; 36: 293-302
11 De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, Davi G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1: 250-256
12 Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003; 14: 213-218
13 Kotlyar E, Vita JA, Winter MR, Awtry EH, Siwik DA, Keaney JF Jr, Sawyer DB, Cupples LA, Colucci WS, Sam F. The relationship between aldosterone, oxidative stress, and inflammation in chronic, stable human heart failure. J Card Fail 2006; 12: 122-127
14 Schwedhelm E, Bartling A, Lenzen H, Tsikas D, Maas R, Brummer J, Gutzki FM, Berger J, Frolich JC, Boger RH. Urinary 8-iso-prostaglandin F2alpha as a risk marker in patients with coronary heart disease: a matched case-control study. Circulation 2004; 109: 843-848
15 Wolfram R, Oguogho A, Palumbo B, Sinzinger H. Enhanced oxidative stress in coronary heart disease and chronic heart failure as indicated by an increased 8-epi-PGF(2alpha). Eur J Heart Fail 2005; 7: 167-172
16 Hozawa A, Ebihara S, Ohmori K, Kuriyama S, Ugajin T, Koizumi Y, Suzuki Y, Matsui T, Arai H, Tsubono Y, Sasaki H, Tsuji I. Increased plasma 8-isoprostane levels in hypertensive subjects: the Tsurugaya Project. Hypertens Res 2004; 27: 557-561
17 Walsh SW, Vaughan JE, Wang Y, Roberts LJ 2nd. Placental isoprostane is significantly increased in preeclampsia. FASEB J 2000; 14: 1289-1296
18 Zanconato S, Carraro S, Corradi M, Alinovi R, Pasquale MF, Piacentini G, Zacchello F, Baraldi E. Leukotrienes and 8-isoprostane in exhaled breath condensate of children with stable and unstable asthma. J Allergy Clin Immunol 2004; 113: 257-263
19 Thompson HJ, Heimendinger J, Haegele A, Sedlacek SM, Gillette C, O’Neill C, Wolfe P, Conry C. Effect of increased vegetable and fruit consumption on markers of oxidative cellular damage. Carcinogenesis 1999; 20: 2261-2266
20 Wang JF, Schramm DD, Holt RR, Ensunsa JL, Fraga CG, Schmitz HH, Keen CL. A dose-response effect from chocolate consumption on plasma epicatechin and oxidative damage. J Nutr 2000; 130: 2115S-2119S
21 Tohgi H, Konno S, Tamura K, Kimura B, Kawano K. Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin. Stroke 1992; 23: 1400-1403
22 Crawford DR, Reyna RS, Weiner MW. Effects of in vivo and in vitro dialysis on plasma transaminase activity. Nephron 1978; 22: 418-422
23 Solberg HE, Theodorsen L, Stromme JH. gamma-Glutamyltransferase in human serum: an analysis of kinetic models. Clin Chem 1981; 27: 303-307
24 Nourooz-Zadeh J. Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes. Methods Enzymol 1999; 300: 13-17
25 Morrow JD, Harris TM, Roberts LJ 2nd. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifications for measurement of eicosanoids. Anal Biochem 1990; 184: 1-10
26 Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation in vivo. J Biol Chem 1999; 274: 24441-24444
27 Kovacs EJ, Messingham KA. Influence of alcohol and gender on immune response. Alcohol Res Health 2002; 26: 257-263
28 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994; 270: 414-423
29 Zima T, Fialova L, Mestek O, Janebova M, Crkovska J, Malbohan I, Stipek S, Mikulikova L, Popov P. Oxidative stress, metabolism of ethanol and alcohol-related diseases. J Biomed Sci 2001; 8: 59-70
30 Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94: 19-25
31 Roberts LJ 2nd, Moore KP, Zackert WE, Oates JA, Morrow JD. Identification of the major urinary metabolite of the F2-isoprostane 8-iso-prostaglandin F2alpha in humans. J Biol Chem 1996; 271: 20617-20620
Figure 1 Flow chart of the improved ELISA for plasma 8-isoprostane.
Figure 2 Results of the second extraction step using an NH2 Sep-Pac column to isolate the plasma 8-isoprostane. Spiked plasma samples containing 3H-labeled 8-isoprostane, PGF2α, TXB2, 6-keto-PGF1, PGE2 or PGD2 were used. Samples extracted with ODS gel were used to assess the absorption by, washing and elution from the NH2 Sep-Pac column.
Figure 3 Dilution curves of plasma 8-isoprostane in 3 different plasma samples [(triangle) y = 227.6x-2.34, r = 0.999 ; (square) y = 126.3x + 0.06, r = 1.000; (diamond) y = 21.8x-0.04, r = 0.999].
Figure 4 Changes in AST, ALT, γ-GTP and plasma 8-isoprostane after alcohol intake. The levels of plasma 8-isoprostane in the 3 individuals increase signifi cantly on d 1 after drinking, but return to their original levels on d 2. No significant changes are observed in AST, ALT and γ-GTP.
Figure 5 Effect of smoking habit on plasma 8-isoprostane levels. The levels of plasma 8-isoprostane were not signifi cantly different between non smokers and smokers (21.5 ± 7.3 vs 22.8 ± 7.4 ng/L).
Source: World J Gastroenterol 2006 September 28;12(36):5846-5852.
Source: World J Gastroenterol 2006 September 28;12(36):5846-5852
Materials and methods
After informed consent was obtained, 157 healthy volunteers (83 males and 74 females; age 36.2 ± 8.4 years) were enrolled in this study. The information on drinking and smoking habits was collected by questionnaire. Volunteers were asked the frequency of drinking (nondrinker, rare drinking, 1-2 times/wk, 3-5 times/wk, almost every day), and smoker or nonsmoker. Various lipid parameters (TC, TG, LDL-C, HDL-C, ApoA-I, apoB, apoE and Lp (a)) were measured by EDTA・2Na, and hepatic functions (AST, ALT and g-GTP) were measured by serum. Blood samples for plasma 8-isoprostane assay were collected in the specific tubes containing 10 mmol/L EDTA・3Na, 20 kU/L Trasylol and 0.1 mmol/L indomethacin, and were separated within 4 h in an ice cooling both. Among the 157 subjects, plasma (heparin) samples were also collected from 3 healthy volunteers to test whether these samples could be used interchangeably for the 8-isoprostane assay. Furthermore, another 3 healthy volunteers as control subjects (2 males, 1 female; age 36.2 ± 8.4 years) were given alcohol (0.5-1.3 g/kg), and their plasma 8-isoprostane, serum AST, ALT, and g-GTP were measured on D1 (ca. 12 h) and 2 (ca. 36 h) after drinking to investigate the influence of alcohol on these levels. All plasma and serum samples were stored at -80℃ until analysis.
Extraction of 8-isoprostane from plasma samples
A two-step solid-phase extraction procedure that was previously used for quantifying plasma TXA2 was modified for the purification of plasma 8-isoprostane. In principle, the first step of the extraction was performed to remove proteins and lipids using ODS gel (ODS-Q3; Fuji Gel, Tokyo, Japan) and the second step was used to separate 8-isoprostane from its analogues and related compounds using an NH2 Sep-Pac column (Sep-Pak Vac NH2; Waters, MA, USA). To optimize the extraction conditions, 3H-labeled 8-isoprostane and other related compounds including PGF2a, TXB2, 6-keto-PGF1, PGE2 and PGD2 (Cayman Chemical, MI, USA) were used as spiked tracers.
Extraction and measurement of 8-isoprostane
The detailed procedure for plasma 8-isoprostane extraction is shown in Figure 1. One milliliter of ODS gel suspension (80 mg silica gel ODS-Q3 in 0.1 mol/L HCl containing 40 mL/L ethanol) was mixed with 0.5 mL of plasma and allowed to stand at room temperature for 5 min. The gel was collected by centrifugation and washed twice with 1 mL of 0.03 mol/L HCl containing 150 mL/L ethanol and once with 1 mL of petroleum ether to remove proteins and lipids. 8-isoprostane was eluted from the gel twice using 1 mL of ethyl acetate for each elution. The eluates were combined, transferred to another test tube and dried under N2 gas. The residue containing 8-isoprostane was dissolved in 1 mL of solution A (hexane: 2-propanol: acetic acid = 90:10:0.5, V/V/V), and applied to an NH2 Sep-Pak column pre-equilibrated with solution A. The column was washed once with 5 mL of solution A, followed by another wash with 5 mL of solution B (hexane: 2-propanol: acetic acid = 75:25:0.5, V/V/V). Finally, 8-isoprostane was eluted from the column with solution C (hexane: 2-propanol: acetic acid = 45:55:0.5, V/V/V) and dried under N2 gas. The residue was dissolved in 1 mL of the assay buffer included in the 8-isoprostane ELISA kit (Cayman Chemical). The ELISA was performed according to the manufacturer’s instructions without further purification of the samples, and the absorbance was measured with a plate reader (V-Max; Molecular Dynamics, NJ, USA). The 8-isoprostane standards included in the ELISA kit were extracted in the same way as the samples to obtain a calibration curve, which was used to estimate the 8-isoprostane levels in the samples.
Effect of interfering substances on the assay
Interference with the 8-isoprostane assay was tested before and after the addition of free and conjugated-bilirubin (up to 342 mmol/L), hemoglobin (up to 5 g/L) and triacylglycerol (up to 55 mmol/L) to each plasma sample. A concentrated reagent set of the interfering substances was purchased from International Reagents Co. Ltd. (Hyogo, Japan).
Storage stability of plasma 8-isoprostane under various conditions
Plasma samples were collected from the 3 control subjects using special tubes as described above. Aliquots of the samples were separately stored at -80℃, 4℃ and 25℃. The 8-isoprostane levels were tested within 4 h after the blood collection and on d 1, 3, 7, 14, 21, 28 and 120 using fresh aliquots of the samples at each time point.
Determination of other lipid profiles and hepatic functions in blood samples
The concentration of TC, TG, LDL-C and HDL-C were determined by an enzymatic method (Kyowa Medics Co. Ltd, Tokyo, Japan). ApoA-I, apoB, apoE and Lp (a) were measured by using immunoturbidimetric assay kits (Daiichi Pure Chemicals Co. Ltd., Tokyo, Japan). AST and ALT were determined using UV method and g-GTP were determined by L-g-glutamyl-3-carboxy-4-nitroanilid substrate method.
Genotyping of ALDH2
DNA was extracted from blood samples collected with EDTA・2Na using a commercially available kit (Sanko Pure Chemicals Co. Ltd., Tokyo, Japan). Mismatched PCR primers for determining the ALDH2 genotypes were designed with reference to the ALDH2 gene sequence (GenBank Accession No. AH002599). The wild-type allele (ALDH2*1) of ALDH2 was amplified using the forward and reverse primers CAAATTACAGGGTCAACTGCTATG and CCACACTCACAGTTTTCACTTC, respectively. The mutant type (ALDH2*2) of ALDH2 was amplified using the forward and reverse primers CAAATTACAGGGTCAACTGCTATG and CCACACTCACAGTTTTCACTTT, respectively. Amplification was performed in 25 mL of 1 × Qiagen PCR buffer containing 0.2 mmol/L of each ALDH2 primer, 200 mmol/L of each dNTP, and 2 U of HotStartTaq DNA polymerase (Qiagen, Hilden, Germany). The PCR conditions were denaturation at 95℃ for 10 min, followed by 35 cycles of amplification (30 s at 94℃, 30 s at 58℃ and 30 s at 72℃). After electrophoresis in a 25 g/L agarose gel, the 135-bp PCR products were stained with ethidium bromide and visualized under UV light.
Statistical analyses of the data were performed by the paired t-test using the In Stat computer software (version 3.06; GraphPad Software Inc.). The correlation between two variables was calculated by the non-parametric Spearman rank coefficient test. A corrected value of P
Extraction of plasma 8-isoprostane
Using 3H-labeled 8-isoprostane and its related compounds as spiked tracers, optimal conditions for the two-step solid-phase extraction of plasma 8-isoprostane were carefully determined. The method was based on a procedure used in a radioimmunoassay for serum TXA2. First, the plasma samples were treated with reverse-phase ODS gel to remove proteins and lipids. The 8-isoprostane bound to the gel was then eluted and separated from its related compounds on a Sep-Pac NH2 column by stepwise elution with increasing concentrations of 2-propanol in the eluent. As shown in Figure 2, most of the 8-isoprostane eluted from the column at 55% 2-propanol, whereas the other compounds eluted at 10%-25% 2-propanol. The average yield of plasma 8-isoprostane in the overall extraction was estimated to be 67.1% by counting the 3H-labeled 8-isoprostane in 5 spiked plasma samples.
Quantification of extracted 8-isoprostane by ELISA
Since it has been shown that plasma 8-isoprostane can be accurately measured using a commercially available ELISA kit after the two-step extraction, we next evaluated the analytical performance and accuracy of the overall ELISA for plasma 8-isoprostane. The detection limit of the ELISA kit was 2.2 ng/L, and this was defined as the concentration corresponding to the optical density of the zero calibrator plus 2SD. The reproducibility of this method estimated using the plasma samples from 3 control subjects was 4.2%-6.3% for the within-run (8 repeats) and 0.8%-8.1% for the between-run (5 repeats) , respectively. To assess the linearity of the assay, the above mentioned plasma samples were diluted serially, extracted and measured for their 8-isoprostane levels. A good dilution linearity was obtained for the assay, as shown in Figure 3. Analytical recovery studies were carried out using 3 plasma samples containing 3 different concentrations of 8-isoprostane, revealing that the recovery rate ranged from 95.9%-97.8%. There were no significant differences between the 8-isoprostane levels in serum and those of the plasma collected with heparin, EDTA or EDTA + ｔrasirol + indomethacin. All of the samples were freshly prepared and subjected to assay. No interference in the assay was observed for hemoglobin (up to 5 g/L), free bilirubin (up to 342 mmol/L), conjugated bilirubin (up to 342 mmol/L) or triacylglycerol (up to 55 mmol/L).
Storage stability of plasma 8-isoprostane
The 8-isoprostane in the plasma samples was stable for at least 120 d at -80℃, as long as freezing and thawing were avoided. However, 2 cycles of freezing at -80℃ and thawing at room temperature decreased the apparent 8-isoprostane levels by 30%. It was previously reported that plasma 8-isoprostane was stable for 6 mo at -80℃, and increased approximately 1.4-fold after 3 cycles of freeze and thawing. Although the reason for this disagreement is not clear, it may be attributed to the method of blood collection, since we used blood collection tubes containing 10 mmol/L EDTA・3Na, 20 kU/L trasylol and 0.1 mmol/L indomethacin, while they used common evacuated tubes containing EDTA・2Na (2.5 mmol/L). The EDTA and indomethacin could function to prevent the induction of new synthesis of 8-isoprostane in plasma samples during storage. When the plasma samples were stored at 4℃, 8-isoprostane levels increased rapidly after 1 wk and were 3-4-fold higher after 28 d. When the samples were stored at 25℃, 8-isoprostane levels reached 15-50-fold the original values after 28 d.
Association of plasma 8-isoprostane levels with drinking habits
The mean level of the plasma 8-isoprostane in 157 healthy subjects using our method was 20.9 ± 9.3 ng/L and no age or gender differences were observed. For the drinking habits obtained by questionnaire, the subjects of each gender were divided into three groups according to their alcohol consumption, namely non-habitual drinkers (nondrinker, rare drinking ,Group I, n = 64), moderate drinkers (1-2 times drinking/wk Group II, n = 56), and habitual drinkers (3-5 times drinking /wk, Group III, n = 37), and the plasma 8-isoprostane levels were compared among these groups. In females, the plasma 8-isoprostane levels were significantly higher in Group Ⅲ (30.0 ± 10.3 ng/L) than in Group I (18.1 ± 5.0 ng/L, P Ⅱ (20.8 ± 6.6 ng/L, P Ⅲ were elevated in both genders (males: 488 ± 335 nkat/L at 37℃; females: 298 ± 185 nkat/L at 37℃) compared with those in Group I (males: 343 ± 253 nkat/L at 37℃; females: 220 ± 70 nkat/L at 37℃; P g-GTP and various lipid parameters (TC, TG, LDL-C, HDL-C, ApoA-I, apoB and Lp(a)) in the subjects (Table 2).
Next, the subjects in each group were further divided into 3 groups according to their ALDH2 genotypes, and the plasma 8-isoprostane levels were compared along with those of AST, ALT and g-GTP. For both the ALDH2*1/1 and ALDH2*2/1 genotypes, the plasma 8-isoprostane level was significantly higher in Group Ⅲ than that in Groups I and Ⅱ (Table 3) in both genders. This tendency was more prominent in females with the ALDH2*21/1 genotype. Especially, the 8-isoprostane level was significantly higher in female habitual drinkers with the ALDH2*2/1 than those with the ALDH2*1/1 genotype (41.2 ± 12.3 vs 26.9 ± 7.7 ng/L, P ALDH2*1/2 genotype was significantly higher in Group Ⅲ than in Group Ⅱ (22.3 ± 9.2 vs 17.1 ± 2.5 nkat/L at 37℃, P g-GTP level was significantly higher in subjects with the ALDH2*1/1 genotype than those with the ALDH2*1/2 genotype (478 ± 396 vs 303 ± 198 nkat/L at 37℃, P g-GTP. Plasma 8-isoprostane significantly increased on d 1, and returned to its original level on d 2 (Figure 4).
Association of plasma 8-isoprostane with smoking habits
The same population of 157 healthy subjects were divided into two groups: non-smokers (n = 96; age 36.7 ± 8.2 years) and smokers (n = 61; age 35.3 ± 8.7 years), and their plasma 8-isoprostane levels were compared. As shown in Figure 5, no significant difference of plasma 8-isoprostane level was observed between these two groups (21.5 ± 7.3 vs 22.8 ± 7.4 pg/mg)
A number of studies have revealed that oxidative stress plays important roles in the pathogenesis of various diseases, such as cancer, diabetes and atherosclerosis[1,2]. The 8-isoprostane present in biological fluids is produced from arachidonic acid by a non-enzymatic, free radical-catalyzed reaction, and has been proposed as a reliable marker for lipid peroxidation and oxidative stress in vivo. 8-Isoprostane is chemically stable, in contrast to other conventional markers of oxidative stress, and its levels in either plasma or urine are elevated in subjects who smoke[4-8] and ingest alcohol[9,10],as well as in patients with diabetes mellitus, heart disease[12-15], hypertension, preeclampsia and asthma. Urinary 8-isoptostane levels increase during the progression of alcohol-induced liver disease and are decreased by abstinence. However, accurate measurement of 8-isoptostane is not easy and requires special instruments, such as GC/MS or LC/MS, since various types of analogues and metabolites are present in biological fluids. For instance, the plasma and urinary 8-isoprostane levels determined by a recently developed immunoassay were much higher than those obtained by GC/MS or LC/MS assays[19,20]. This could be attributed to cross-reaction of the 8-isoprostane analogues and metabolites in the samples with the 8-isoprostane antibody used in the immunoassay. In this study, we developed a new method for pretreatment before analyzing by the commercially available ELISA kit, and performed various examinations for accurate assay of 8-isoprostane. Using this method, we examined the effects of drinking and smoking habits against the levels of plasma 8-isoprostane in healthy Japanese volunteers.
Improved method of plasma 8-Isoprostane measurement and association analyses with habitual drinking and smoking
Soichi Kitano, Hisashi Hisatomi, Nozomu Hibi, Katsumi Kawano, Shoji Harada
Soichi Kitano, Hisashi Hisatomi, Nozomu Hibi, Katsumi Kawano, Technology Development Department, SRL Inc., Hachioji, Tokyo, Japan
Shoji Harada, Center for Molecular Biology and Cytogenetics, SRL Inc. , Hino, Tokyo, Japan
Correspondence to: Soichi Kitano, Development Planning Section, Technology Development Department, SRL Inc., 5-6-50 Shinmachi, Hino-shi, Tokyo, 191-0002, Japan. [email protected]
AIM: To develop a simple and accurate method for quantifying 8-isoprostane in plasma by employing a combination of two-step solid-phase extraction of samples and a commercially available ELISA kit, and by this method to examine the effects of drinking and smoking habits against the levels of plasma 8-isoprostane in healthy Japanese volunteers.
METHODS: Plasma 8-isoprostane was extracted with ODS gel suspension followed by NH2 Sep-Pak column. The 8-isoprostane fractions were assayed using a commercially available ELISA kit. We measured plasma 8-isoprostane levels in 157 healthy Japanese volunteers divided into three groups (64 non-habitual drinkers, 56 moderate drinkers and 37 habitual drinkers) according to their alcohol consumption per week. Genotypes of aldehyde dehydrogenase 2 (ALDH2) were also determined to investigate the plasma 8-isoprostane levels with reference to drinking habits. In addition, the plasma 8-isoprostane levels of 96 non-smokers and 61 smokers from the same subjects were compared.
RESULTS: Our method fulfilled all the requirements for use in routine clinical assays with respect to sensitivity, intra- and inter-assay reproducibility, accuracy and dynamic assay range. Significant increases of plasma 8-isoprostane levels were observed in female habitual drinkers when compared with those of non-habitual drinkers (t = 5.494, P
CONCLUSION: Our present method was proved to be a simple and accurate tool for measuring plasma 8-isoprostane. However, the clinical utility of plasma 8-isoprostane for drinking and smoking habits was limited since elevated 8-isoprostane levels were observed in female heavy drinkers, and no association was found between smokers and nonsmokers.
Key words: 8-Isoprostane; ELISA; Lipid peroxidation; Drinking; Smoking
Source: World J Gastroenterol 2006 September 28;12(36):5846-5852.